Lilly's $8bn acquisition of genetics-based cancer specialist Loxo Oncology didn't involve any other bidders and was finalized in just days over the holidays as Lilly sought to make a news splash at the J.P. Morgan Healthcare conference, according to an SEC filing.
Eli Lilly & Co.'s $8bn acquisition of genetics-based cancer specialist Loxo Oncology Inc. happened quickly and without any other bidders involved, according to filings with the Securities & Exchange Commission outlining how the deal materialized.
Lilly raised its offer for Loxo just once from $230 per share to $235 per share before it was accepted...
Create an account to read this article
Already a subscriber?
Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.
Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.
SEC filings reveal that Merck was the sole bidder for Verona and its COPD drug Ohtuvayre, with the final $10bn deal wrapped up within a month.
Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline
Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.
In this week's episode: Trump ups pressure on MFN pricing; Pfizer says pharma working with Trump on direct sales; Sanofi says direct sales worth considering: Aurigene Oncology CEO on biotech valuations and more; and Novartis progresses pipeline-in-a-product assets.
BeBetter becomes first unprofitable innovative drug maker to have application for an IPO on Shanghai's STAR Market cleared by China’s top securities regulator, while Trinomab becomes first among peers to have IPO filing accepted.
